Market Overview

Aptinyx Represents Untapped Value, BMO Says


Aptinyx Inc (NASDAQ: APTX) reported second-quarter results ahead of expectations and expressed confidence in its cash lasting into 2021.

The company has an ongoing Phase 2 study and is progressing towards initiating another three by the end of 2019. All four are “meaningful” clinical programs and expected to read out in 2020-2021, according to BMO Capital Markets.

The Analyst

BMO’s Gary Nachman maintained an Outperform rating on Aptinyx, with a price target of $15.

The Thesis

Aptinyx reported a beat largely on lower expenses resulting from timing, Nachman said.

Revenue came in at $900,00 million, slightly shy of the consensus estimate of $1 million. The company recorded a loss per share of 36 cents, significantly better than the consensus expectation of 52 cents. The company is managing costs carefully and is confident that its cash will last into 2021, the analyst said.

Aptinyx is conducting Phase II trials for NYX-783 in PTSD and expects to begin three additional key Phase II studies by yearend. This includes two large Phase II studies for its lead compound NYX-2925 in advanced DPN (diabetic peripheral neuropathy) and fibromyalgia as well as a Phase II study for NYX-458 in Parkinson's CI (cognitive impairment).

Price Action

Shares of Aptinyx fell more than 11% to $3.22 on Tuesday.

Related Links:

Benzinga's Top Upgrades, Downgrades For August 13, 2019

The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

Latest Ratings for APTX

Aug 2019DowngradesNeutralUnderweight
Mar 2019MaintainsOverweightOverweight
Jan 2019DowngradesOverweightNeutral

View More Analyst Ratings for APTX
View the Latest Analyst Ratings

Posted-In: BMO Capital Markets Gary NachmanAnalyst Color Analyst Ratings


Related Articles (APTX)

View Comments and Join the Discussion!

Latest Ratings

WUBABOCOM InternationalDowngrades
DLTROTR GlobalUpgrades
ARCCCompass PointDowngrades
GTYHCitiInitiates Coverage On7.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Tilray Posts Wider-Than-Expected Q2 Loss, Revenue Beat

OptiNose's Q2 Results Reflect Strong Underlying Trends, RBC Says